Head to Head Survey: Caribou Biosciences (NASDAQ:CRBU) and Tourmaline Bio (NASDAQ:TRML)

Caribou Biosciences (NASDAQ:CRBU) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Caribou Biosciences and Tourmaline Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0	1	3	0	2.75
Tourmaline Bio	0	0	6	0	3.00

Caribou Biosciences currently has a consensus price target of $22.50, suggesting a potential upside of 475.45%. Tourmaline Bio has a consensus price target of $61.80, suggesting a potential upside of 294.64%. Given Caribou Biosciences’ higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Tourmaline Bio.

Institutional & Insider Ownership

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 16.5% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Caribou Biosciences and Tourmaline Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-296.05%	-31.06%	-25.73%
Tourmaline Bio	N/A	-30.86%	-29.30%

Valuation & Earnings

This table compares Caribou Biosciences and Tourmaline Bio’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$34.48 million	10.24	-$102.07 million	($1.45)	-2.70
Tourmaline Bio	N/A	N/A	-$42.12 million	($11.35)	-1.38

Tourmaline Bio has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Caribou Biosciences has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500.

Summary

Tourmaline Bio beats Caribou Biosciences on 8 of the 13 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.